Irani SR et al. reported that a high percentage (50%) of patients among 9 people with anti-LGI1 activity demonstrated skin reactions caused by the use of ASMs (2 PHT, 2 CBZ, and 1 VPA) (34). The gene discussed is LGI1; the disease is skin reaction.